T1	PROC 49 63	ensayo clínico
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	CHEM 80 90	apremilast
#2	AnnotatorNotes T2	C1678805; apremilast; Organic Chemical · Pharmacologic Substance
T3	DISO 129 148	psoriasis en placas
#3	AnnotatorNotes T3	C0263361; Psoriasis vulgaris; Disease or Syndrome
T4	PROC 255 296	Estudio abierto y multicéntrico de fase 2
T5	PROC 302 355	evaluar la seguridad, tolerabilidad y farmacocinética
T6	CHEM 359 369	apremilast
#4	AnnotatorNotes T6	C1678805; apremilast; Organic Chemical · Pharmacologic Substance
T7	DISO 410 429	psoriasis en placas
#5	AnnotatorNotes T7	C0263361; Psoriasis vulgaris; Disease or Syndrome
T8	DISO 476 495	Psoriasis en placas
#6	AnnotatorNotes T8	C0263361; Psoriasis vulgaris; Disease or Syndrome
T9	DISO 522 541	Psoriasis en placas
#7	AnnotatorNotes T9	C0263361; Psoriasis vulgaris; Disease or Syndrome
T10	PROC 748 762	diagnosticados
#8	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	DISO 767 786	psoriasis en placas
#9	AnnotatorNotes T11	C0263361; Psoriasis vulgaris; Disease or Syndrome
T12	DISO 813 831	Afecciones médicas
T13	PROC 868 891	análisis de laboratorio
#10	AnnotatorNotes T13	C0022885; Laboratory Procedures; Laboratory Procedure
T14	DISO 893 916	enfermedad psiquiátrica
#11	AnnotatorNotes T14	C0004936; Mental disorders; Mental or Behavioral Dysfunction
T15	CHEM 371 379	CC-10004
#12	AnnotatorNotes T15	C3658170; CC 10004; Organic Chemical · Pharmacologic Substance
T16	Date 13 17	2015
T18	LIVB 104 109	niños
#13	AnnotatorNotes T18	C0008059; Child; Age Group
T20	PHYS 340 355	farmacocinética
#14	AnnotatorNotes T20	C0031327; Drug Kinetics; Physiologic Function
T21	LIVB 384 405	pacientes pediátricos
#15	AnnotatorNotes T21	C0030705; Patients; Patient or Disabled Group + C0008059; Child; Age Group
T22	Age 589 604	de 12 a 17 años
T23	LIVB 628 633	niños
#16	AnnotatorNotes T23	C0008059; Child; Age Group
T24	Age 642 656	de 6 a 11 años
T25	LIVB 702 726	Pacientes de ambos sexos
#17	AnnotatorNotes T25	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T26	Age 730 747	entre 6 y 17 años
T28	LIVB 931 939	paciente
#18	AnnotatorNotes T28	C0030705; Patients; Patient or Disabled Group
T30	LIVB 1005 1013	paciente
#19	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 112 124	adolescentes
#20	AnnotatorNotes T31	C0205653; Adolescent (age group); Age Group
T36	LIVB 568 580	adolescentes
#21	AnnotatorNotes T36	C0205653; Adolescent (age group); Age Group
A1	Population_data T18 Age
A2	Population_data T31 Age
A3	Population_data T21 Age
A4	Population_data T36 Age
A5	Population_data T23 Age
#22	AnnotatorNotes T4	C1709323; Open Label Study; Research Activity + C1096776; Multicenter Study; Research Activity + C0282460; Phase 2 Clinical Trials; Research Activity
#23	AnnotatorNotes T5	C0201734; Pharmacokinetic study; Research Activity + C1705187; Safety Study; Research Activity + C3274448; Tolerability Study; Research Activity
#24	AnnotatorNotes T12	C0221423; Illness (finding); Sign or Symptom
T17	Neg_cue 921 927	impide
T19	Observation 940 964	participar en el estudio
A6	Assertion T19 Negated
R1	Negation Arg1:T17 Arg2:T19	
T27	Observation 995 1001	riesgo
R3	Experiences Arg1:T30 Arg2:T27	
R4	Causes Arg1:T12 Arg2:T27	
R5	Causes Arg1:T14 Arg2:T27	
R6	Before Arg1:T14 Arg2:T19	
R7	Before Arg1:T12 Arg2:T19	
T29	Observation 845 891	resultados anómalos en análisis de laboratorio
R8	Before Arg1:T29 Arg2:T19	
R9	Causes Arg1:T29 Arg2:T27	
T32	Quantifier_or_Qualifier 832 843	importantes
#25	AnnotatorNotes T32	C3898777; Important; Qualitative Concept
R10	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T32	
T33	ANAT 195 204	organismo
#26	AnnotatorNotes T33	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
R11	Experiences Arg1:T31 Arg2:T3	
R12	Experiences Arg1:T18 Arg2:T3	
T34	Spec_cue 77 79	si
T35	Quantifier_or_Qualifier 94 100	seguro
A7	Assertion T35 Speculated
R13	Speculation Arg1:T34 Arg2:T35	
R14	Experiences Arg1:T18 Arg2:T2	
R15	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T35	
R16	Experiences Arg1:T31 Arg2:T2	
T37	Quantifier_or_Qualifier 149 171	entre moderada y grave
#27	AnnotatorNotes T37	C1299393; Moderate to severe; Qualitative Concept
R17	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T37	
T38	Quantifier_or_Qualifier 430 452	entre moderada y grave
#28	AnnotatorNotes T38	C1299393; Moderate to severe; Qualitative Concept
R18	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T38	
R19	Experiences Arg1:T21 Arg2:T20	
R20	Experiences Arg1:T21 Arg2:T6	
R21	Experiences Arg1:T21 Arg2:T15	
R22	Experiences Arg1:T21 Arg2:T7	
T39	Quantifier_or_Qualifier 542 564	entre moderada y grave
#29	AnnotatorNotes T39	C1299393; Moderate to severe; Qualitative Concept
R23	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T39	
R24	Experiences Arg1:T36 Arg2:T9	
R25	Has_Age Arg1:T36 Arg2:T22	
R26	Has_Age Arg1:T23 Arg2:T24	
R27	Experiences Arg1:T23 Arg2:T9	
R28	Has_Age Arg1:T25 Arg2:T26	
R29	Experiences Arg1:T25 Arg2:T11	
#30	AnnotatorNotes T29	C3648370; laboratory tests nonspecific abnormal findings; Finding
R30	Experiences Arg1:T28 Arg2:T29	
R31	Experiences Arg1:T28 Arg2:T13	
R32	Experiences Arg1:T28 Arg2:T12	
R33	Experiences Arg1:T28 Arg2:T14	
R34	Experiences Arg1:T28 Arg2:T27	
R36	Experiences Arg1:T30 Arg2:T14	
R37	Experiences Arg1:T30 Arg2:T29	
R38	Experiences Arg1:T30 Arg2:T12	
T40	CONC 974 983	inclusión
#31	AnnotatorNotes T40	C1512693; Inclusion; Qualitative Concept
R40	Before Arg1:T40 Arg2:T27	
#32	AnnotatorNotes T27	C0559571; At risk; Finding
#33	AnnotatorNotes T19	C1278516; Patient participation status; Finding
R2	Experiences Arg1:T30 Arg2:T13	
A8	Experiencer T18 Patient
A9	Experiencer T31 Patient
A10	Experiencer T21 Patient
A11	Experiencer T36 Patient
A12	Experiencer T23 Patient
A13	Experiencer T25 Patient
A14	Experiencer T28 Patient
A15	Experiencer T30 Patient
